55.7 F
San Diego
Tuesday, Mar 19, 2024
-Advertisement-

International Stem Cell Secures Patent

International Stem Cell Corp. of Oceanside said it has been granted a patent relating to the development of human parthenogenetic stem cells, a key step toward licensing its technology to others.

The patent protects the company’s technology, a process that involves the coaxing of unfertilized eggs into the blastocyst stage, when it is an embryo of about 200 cells. ISCO has touted the advancement as a major step toward regenerative medicine without the destruction of human embryos or immune rejection issues.

The company first announced creation of the cells in 2007, but said the latest development allows it to share its knowledge with other researchers through partnerships, joint ventures and funded research and licensing arrangements.

“International Stem Cell Corporation is particularly proud of these accomplishments because we have been funded thus far entirely by investors, without NIH or other governmental aid,” said Jeffrey Janus, senior vice president of ISCO.

He said he expects that the cells will be increasingly used in government funded studies once proven to exhibit similar characteristics as embryonic stem cells.

— Heather Chambers

-Advertisement-

Featured Articles

Oberon Eyes Europe for Renewable DME

Leaders of Influence in Law 2024

-Advertisement-
-Advertisement-

Related Articles

-Advertisement-
-Advertisement-
-Advertisement-